key: cord-0734030-8rlh8lep
authors: Kahn, Fredrik; Shannon, Oonagh; Björck, Lars
title: Suggested treatment of serious complications to COVID‐19 vaccination with IdeS, a bacterial antibody‐cleaving enzyme
date: 2021-07-09
journal: J Thromb Haemost
DOI: 10.1111/jth.15433
sha: 0720e1b0d7c907b27a1e58122ec6aacd2b554993
doc_id: 734030
cord_uid: 8rlh8lep

Several recent reports have independently described a rare thrombosis with thrombocytopenia syndrome (TTS) post vaccination with ChAdOx1 nCoV-19. In J. Thromb. Haemost., Ankerlund Blauenfeldt et al. [1] described the clinical presentation of a case of fatal acute ischemic stroke associated with profound thrombocytopenia. The pathogenesis behind this case may involve mechanisms similarly to autoimmune heparin-induced thrombocytopenia (HIT) since anti-platelet factor 4(PF-4) antibodies were detected in the patient plasma.

Several recent reports have independently described a rare throm- 

IgG with a unique degree of specificity; no other substrate has been identified. 5 The enzyme cleaves human IgG (all four human subclasses are cleaved) in the lower hinge region generating one F(ab´) 2 fragment and two Fc halves. Before cleavage can occur, IdeS has to bind to the Fc region, and the extreme specificity is explained by the requirement for this initial protein--protein interaction. In many autoimmune conditions and in transplant rejection IgG antibodies play a pathogenic role. The specific cleavage of IgG by IdeS indicated that the proteinase could potentially be used to disarm pathogenic IgG antibodies in vivo, and several studies demonstrated the ability of IdeS to abolish IgG-mediated diseases in animal models of autoimmune conditions. In this context it is important to highlight that IgG antibodies contained in immune complexes are fully available for IdeS cleavage. 4 In relation to the theme of this letter, it is interesting that in a mouse model of IgG-mediated thrombocytopenia IdeS treatment rescued 100% of the mice from lethal disease, 6 and that the enzyme has been successfully used to treat HIT in a mouse model. 7 In humans a single intravenous dose of IdeS within minutes cleaves the entire extracellular IgG-pool inactivating IgGFc-mediated effector function. 8 This is important because rapid interventions are required to counteract the complicated pathogenic mechanisms underlying TTS. A therapeutic combination including intravenous immunoglobulin (IVIG) was recently presented in this journal by Thaler et al. 9 IVIG is already indicated as a treatment for several autoimmune diseases including HIT; however, the exact mode of action is not clarified.

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Evaluation of laboratory assays for anti-Platelet Factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

Severe streptococcal infection is associated with M protein-induced platelet activation and thrombus formation

IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G

IdeS: a bacterial proteolytic enzyme with therapeutic potential

Cleavage of anti-PF4/ heparin IgG by a bacterial protease and potential benefit in heparininduced thrombocytopenia

Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase i study with the bacterial enzyme IdeS-A novel therapeutic opportunity

Successful treatment of vaccineinduced prothrombotic immune thrombocytopenia (VIPIT)

IgG endopeptidase in highly sensitized patients undergoing transplantation